ライフサイエンスコーパス: tissue-type plasminogen activator

1 the provisional matrix and the protease tPA (tissue-type plasminogen activator).

2 minogen activator (uPA) and fibrinogen-bound tissue-type plasminogen activator.

3 a dose-dependent fashion in the presence of tissue-type plasminogen activator.

4 not evaluated as early after stroke onset as tissue-type plasminogen activator.

5 or of both urinary plasminogen activator and tissue-type plasminogen activator.

6 tatic interaction between these residues and tissue-type plasminogen activator.

7 activation of cell-associated plasminogen by tissue-type plasminogen activator.

8 okinase-type plasminogen activator (uPA) and tissue-type plasminogen activator.

9 roteinase (MMP)-1 and -9, and urokinase- and tissue-type plasminogen activators.

10 accompanied by up-regulation of the neuronal tissue-type plasminogen activator, a serine protease kno

11 8-bromo-cAMP, causes a dramatic increase in tissue-type plasminogen activator activity secondary to

12 n was demonstrated by complete inhibition of tissue-type plasminogen activator activity with supernat

13 with a corresponding increase in plasma PAI/tissue-type plasminogen activator activity.

14 ith bleeding complications after intravenous tissue-type plasminogen activator administration to pati

15 thway inhibitor) and hyperfibrinolysis (high tissue-type plasminogen activator) (all p < .05 vs. youn

16 ioidosis have elevated circulating levels of tissue-type plasminogen activator, an important regulato

17 ndard of care: intravenous thrombolysis with tissue-type plasminogen activator and endovascular treat

18 vator inhibitor type 1 formed a complex with tissue-type plasminogen activator and inhibited its prot

19 significant reduction in expression both of tissue-type plasminogen activator and of urokinase-type

20 activation of fibrinolysis (plasma levels of tissue-type plasminogen activator and plasmin-alpha2-ant

21 sis was not influenced by TNFR55:IgG (plasma tissue-type plasminogen activator and plasmin-alpha2-ant

22 levels) and the fibrinolytic system (plasma tissue-type plasminogen activator and plasminogen activa

23 lso providing a common binding site for both tissue-type plasminogen activator and plasminogen via it

24 t amorphous protein aggregates interact with tissue-type plasminogen activator and plasminogen, via a

25 However, in tissue-type plasminogen activator and plasminogen-defici

26 ntiation products, two well-known proteases: tissue-type plasminogen activator and urokinase, as well

27 nhibitor-1 (PAI-1), the primary inhibitor of tissue-type plasminogen activator and urokinase, is know

28 t inhibit several serine proteases including tissue-type plasminogen activator and urokinase-type pla

29 <60 minutes in >50% of patients treated with tissue-type plasminogen activator), and (5) face-to-face

30 angioplasty with a 3- to 4-hour infusion of tissue-type plasminogen activator, and 3 compared angiop

31 ligands, including matrix metalloprotease-9, tissue-type plasminogen activator, and alpha(2)-macroglo

32 ed protein, urokinase plasminogen activator, tissue-type plasminogen activator, and plasminogen activ

33 of the fibrinolytic system (plasma levels of tissue-type plasminogen activator, and plasminogen activ

34 ay containing purified thrombin, fibrinogen, tissue-type plasminogen activator, and plasminogen, clot

35 (intercellular adhesion molecule-1, ICAM-1), tissue-type plasminogen activator, and TM-inducible gluc

36 ulted in increased plasminogen activation by tissue-type plasminogen activator, and was dependent on

37 e to four weeks (p < 0.03) and a decrease in tissue-type plasminogen activator antigen from baseline

38 Tissue-type plasminogen activator antigen increased (31%

39 in cholesterol, homocysteine, triglycerides, tissue-type plasminogen-activator antigen, and C-relativ

40 ciated plasmin-induced fibrinolysis and/or a tissue-type plasminogen activator-associated decrease in

41 These effects are related to tissue-type plasminogen activator-associated plasmin-ind

42 plasminogen activator at pH 6.2-8.0 and for tissue-type plasminogen activator at pH 6.2.

43 The LRP1 agonists, alpha2-macroglobulin and tissue-type plasminogen activator, attenuated expression

44 demonstrated that hepsin did not cleave pro-tissue-type plasminogen activator but efficiently conver

45 Canada are limited at present to intravenous tissue-type plasminogen activator, but bleeding complica

46 Intravenous tissue-type plasminogen activator can be beneficial to s

47 uding plasminogen activators (urokinase- and tissue-type plasminogen activators), coagulation enzymes

48 Wild-type and tissue-type plasminogen activator-deficient C57BL/6 mice

49 ng infection with Burkholderia pseudomallei, tissue-type plasminogen activator-deficient mice were pr

50 with an early increase in cytokine levels in tissue-type plasminogen activator-deficient mice.

51 rs formed with decorin underwent accelerated tissue-type plasminogen activator-dependent fibrinolysis

52 conventional approaches such as recombinant tissue-type plasminogen activator, direct thrombin inhib

53 ce, we bred urokinase plasminogen activator, tissue-type plasminogen activator double knockouts.

54 s study, we aimed to investigate the role of tissue-type plasminogen activator during melioidosis.

55 ligands, including alpha2-macroglobulin and tissue-type plasminogen activator, failed to cause LRP1

56 STO (Global Utilization of Streptokinase and Tissue-Type Plasminogen Activator for Occluded Coronary

57 low-dose (25 mg), slow infusion (6 hours) of tissue-type plasminogen activator for the treatment of p

58 lobal Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary

59 Changes in tissue-type plasminogen activator gene expression do not

60 sed by Burkholderia pseudomallei, endogenous tissue-type plasminogen activator has harmful effects wi

61 Tissue-type plasminogen activator, however, is not neces

62 nd more eligible patients to be treated with tissue-type plasminogen activator if onset is </=2 hours

63 dosis was associated with elevated levels of tissue-type plasminogen activator in lungs of infected w

64 tor-1 is the main physiological regulator of tissue-type plasminogen activator in normal plasma.

65 Some studies have shown elevated tissue-type plasminogen activator in pemphigus lesions.

66 1, 2010 and March 31, 2015 and who received tissue-type plasminogen activator in the emergency depar

67 10 patients with IS treated with intravenous tissue-type plasminogen activator in the Get With The Gu

68 n plasma of pregnant women inhibits FXIa and tissue-type plasminogen activator-induced clot fibrinoly

69 formation but did not affect plasminogen and tissue-type plasminogen activator interactions with Fgal

70 ng patients with IS treated with intravenous tissue-type plasminogen activator is associated with hig

71 ents with acute ischemic stroke treated with tissue-type plasminogen activator is associated with imp

72 Intravenous rt-PA (recombinant tissue-type plasminogen activator) is effective in impro

73 s known regarding outcomes after intravenous tissue-type plasminogen activator (IV tPA) therapy for a

74 ulin G caused blisters to the same degree in tissue-type plasminogen activator knockout and control m

75 By interacting with active tissue-type plasminogen activator, LDL receptor-related

76 man plasminogen and facilitated the latter's tissue-type plasminogen activator-mediated activation to

77 -inducing activity of IGFBP3 is inhibited by tissue-type plasminogen activator-mediated proteolysis,

78 nase-type plasminogen activator mRNA but not tissue-type plasminogen activator mRNA correlated with f

79 several partially purified preparations of a tissue-type plasminogen activator mutant (TNK-tPA).

80 n agreement, the influence of plasminogen or tissue-type plasminogen activator on binding of apo(a) t

81 oplasty with "accelerated" administration of tissue-type plasminogen activator over 90 minutes.

82 ts function as an inhibitor of urokinase and tissue-type plasminogen activator (PA), PA inhibitor-1 (

83 ERK phosphorylation was not induced by tissue-type plasminogen activator-PAI-1 complex or by uP

84 ine proteases urinary plasminogen activator, tissue-type plasminogen activator, plasmin and thrombin

85 ytic system (plasminogen activator activity, tissue-type plasminogen activator, plasminogen activator

86 on of fibrinolysis (plasma concentrations of tissue-type plasminogen activator, plasminogen activator

87 of the fibrinolytic system (plasma levels of tissue-type plasminogen activator, plasminogen activator

88 The fibrinolytic variables, tissue-type plasminogen activator, plasminogen activator

89 inogen, factor XIII), fibrinolysis (D-dimer, tissue-type plasminogen activator, plasminogen activator

90 action of apo(a) with the ternary complex of tissue-type plasminogen activator, plasminogen and fibri

91 ronectin, vitronectin, laminin, single-chain tissue-type plasminogen activator, plasminogen, or any p

92 The predictive value of plasma levels of tissue-type plasminogen activator, platelet activator in

93 ms (MT1B/MT1A/MT-1F; from 2.9- to 3.2-fold), tissue-type plasminogen activator precursor (PLAT; 2.8-f

94 the isolated recombinant kringle 2 domain of tissue-type plasminogen activator (r-K2tPA), an amino ac

95 plasminogen activator (t-PA) and recombinant tissue-type plasminogen activator (r-PA).

96 National guidelines endorse recombinant tissue-type plasminogen activator (r-tPA) in eligible pa

97 given to IL-10 (-/-) mice normalized the PAI/tissue-type plasminogen activator ratio, reduced pulmona

98 duced thrombus formation, and an increase in tissue-type plasminogen activator release.

99 Intravenous thrombolysis with tissue-type plasminogen activator remains the mainstay o

100 sttreatment of stroke with recombinant human tissue-type plasminogen activator (rht-PA) constrains th

101 e randomized to a 50-mg bolus of recombinant tissue-type plasminogen activator (rt-PA) (alpha half-li

102 Recombinant tissue-type plasminogen activator (rt-PA) improves outco

103 amma (rIFN-gamma, Actimmune) and recombinant tissue-type plasminogen activator (rt-PA, Activase) to m

104 705 patients received alteplase (recombinant tissue-type plasminogen activator [rt-PA]).

105 will maximally accelerate thrombolysis by r-tissue-type plasminogen activator (rTPA) and reduce resi

106 were exposed to 10 to 1000 ng/mL recombinant tissue-type plasminogen activator (RTPA), urokinase-type

107 Studies on enzymatic activity of tissue-type plasminogen activator show that polynitrosyl

108 An aerosolized fibrinolytic agent, tissue-type plasminogen activator, significantly diminis

109 the chymotrypsin family of serine proteases, tissue type plasminogen activator (t-PA) is not synthesi

110 s 120 times more efficiently by u-PA than by tissue type plasminogen activator (t-PA), an intimately

111 study compared the activities of recombinant tissue-type plasminogen activator (t-PA) and a plasminog

112 s is regulated in part by the interaction of tissue-type plasminogen activator (t-PA) and plasminogen

113 identified the currently available doses of tissue-type plasminogen activator (t-PA) and recombinant

114 for two intimately related serine proteases, tissue-type plasminogen activator (t-PA) and urokinase-t

115 Tissue-type plasminogen activator (t-PA) can modulate pe

116 Tissue-type plasminogen activator (t-PA) has evolved to

117 ptide (TAP), after thrombolytic therapy with tissue-type plasminogen activator (t-PA) in a canine mod

118 Human colon fibroblasts (HCF) produce tissue-type plasminogen activator (t-PA) in culture, but

119 The serine protease tissue-type plasminogen activator (t-PA) initiates the f

120 Tissue-type plasminogen activator (t-PA) is a serine pro

121 The gene encoding tissue-type plasminogen activator (t-PA) is an immediate

122 the vascular endothelium locally to release tissue-type plasminogen activator (t-PA) is critical for

123 the chymotrypsin family of serine proteases, tissue-type plasminogen activator (t-PA) is not synthesi

124 n this study, we demonstrate that VDAC binds tissue-type plasminogen activator (t-PA) on human neurob

125 from all 358 patients with AMI randomized to tissue-type plasminogen activator (t-PA) or primary PTCA

126 ut not noncovalent Michaelis complexes, with tissue-type plasminogen activator (t-PA) or urokinase (u

127 t are efficiently and selectively cleaved by tissue-type plasminogen activator (t-PA) or urokinase-ty

128 t to define the local regulation of vascular tissue-type plasminogen activator (t-PA) release.

129 y of vascular endothelium to locally release tissue-type plasminogen activator (t-PA) represents an i

130 ting enzyme (ACE) inhibition potentiates the tissue-type plasminogen activator (t-PA) response to exo

131 ve 30-day mortality benefit with accelerated tissue-type plasminogen activator (t-PA) versus streptok

132 Tissue-type plasminogen activator (t-PA), for example, p

133 Plasma levels of tissue-type plasminogen activator (t-PA), plasminogen ac

134 1 patients randomized to receive accelerated tissue-type plasminogen activator (t-PA), streptokinase

135 ract differently with streptokinase (SK) and tissue-type plasminogen activator (t-PA), which could re

136 is has been dominated by the experience with tissue-type plasminogen activator (t-PA), which proved l

137 dy, we demonstrate that GRP78 also binds the tissue-type plasminogen activator (t-PA), which results

138 A 15% reduction in mortality for the tissue-type plasminogen activator (t-PA)-treated group w

139 o receive primary angioplasty or accelerated tissue-type plasminogen activator (t-PA).

140 imultaneous decrease in the concentration of tissue-type plasminogen activator (t-PA)/PAI-1 complexes

141 After >/=60 minutes of occlusion, tissue-type plasminogen activator (t-PA; 1.42 mg/kg) was

142 and inflammatory marker proteins (including tissue-type plasminogen activator [t-PA], plasminogen ac

143 l evidence that maspin specifically inhibits tissue-type plasminogen activator that is associated wit

144 solve thrombi acutely and r-tPA (recombinant tissue-type plasminogen activator) therapy may be requir

145 333 patients (24%) who received recombinant tissue-type plasminogen activator, there was also no ben

146 Clots were formed in the presence of tissue-type plasminogen activator, thrombin, phosphatidy

147 In contrast, uPA(-/-) and tissue-type plasminogen activator tPA(-/-) mice, but not

148 Tissue type plasminogen activator (tPA) is a key enzyme

149 urified protein is an efficient inhibitor of tissue type plasminogen activator (tPA), having an appar

150 e FDA approved treatment for acute stroke is tissue type plasminogen activator (tPA).

151 e demonstrate that an increase in endogenous tissue-type plasminogen activator (tPA) activity in the

152 axons at synaptic regions where it controls tissue-type plasminogen activator (tPA) activity.

153 ks urokinase plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) activity.

154 l analysis of fibrinolysis after recombinant tissue-type plasminogen activator (tPA) administration r

155 ing further reduction in treatment times for tissue-type plasminogen activator (tPA) administration.

156 Tissue-type plasminogen activator (tPA) also bound to VS

157 Although both tissue-type plasminogen activator (tPA) and matrix metal

158 t defensin inhibits fibrinolysis mediated by tissue-type plasminogen activator (tPA) and plasminogen.

159 trinsic tryptophan fluorescence of two-chain tissue-type plasminogen activator (tPA) and the proteina

160 The serine proteinase tissue-type plasminogen activator (tPA) and the serine p

161 ptide-blocked PAI-1 was a substrate for both tissue-type plasminogen activator (tPA) and trypsin and

162 Increased expression of tissue-type plasminogen activator (tPA) and urokinase-ty

163 tor-1 (PAI-1) to serine proteinases, such as tissue-type plasminogen activator (tPA) and urokinase-ty

164 teolysis, we explored the regulatory role of tissue-type plasminogen activator (tPA) and urokinase-ty

165 controls; in contrast, transcripts for both tissue-type plasminogen activator (tPA) and urokinase-ty

166 activator inhibitor 1 (PAI-1) that preserved tissue-type plasminogen activator (tPA) and urokinase-ty

167 opulmonary bypass (CPB) on PAI-1 antigen and tissue-type plasminogen activator (tPA) antigen and acti

168 ee measures of plasma fibrinolytic activity: tissue-type plasminogen activator (TPA) antigen, plasmin

169 (Fn) enhances plasminogen (Pg) activation by tissue-type plasminogen activator (tPA) by serving as a

170 Tissue-type plasminogen activator (tPA) catalyzes the ra

171 A fibrinolytic agent consisting of a tissue-type plasminogen activator (tPA) coupled to the s

172 Regulation of tissue-type plasminogen activator (tPA) depends on fibri

173 e hypothesis, namely, that marked release of tissue-type plasminogen activator (tPA) followed by dela

174 Hypoxia induces the release of tissue-type plasminogen activator (tPA) from cerebral co

175 cations of the thrombomodulin (TM) gene, the tissue-type plasminogen activator (tPA) gene, and the ur

176 w bolus fibrinolytics derived from the human tissue-type plasminogen activator (tPA) have emerged as

177 After obstructive injury, mice lacking tissue-type plasminogen activator (tPA) have fewer myofi

178 ates have been synthesized and evaluated for tissue-type plasminogen activator (tPA) hydrolysis in an

179 al trials suggest the benefit of intravenous tissue-type plasminogen activator (tPA) in acute ischemi

180 The benefits of intravenous tissue-type plasminogen activator (tPA) in acute ischemi

181 After stroke, the thrombolytic effect of tissue-type plasminogen activator (tPA) in the intravasc

182 The clinical use of tissue-type plasminogen activator (tPA) in the treatment

183 Assembled A beta is a potent stimulator of tissue-type plasminogen activator (tPA) in vitro.

184 functioning as an activator of fibrinolysis, tissue-type plasminogen activator (tPA) interacts with n

185 Tissue-type plasminogen activator (tPA) is a highly spec

186 Here we show that tissue-type plasminogen activator (tPA) is a potent mito

187 Tissue-type plasminogen activator (tPA) is a serine prot

188 Tissue-type plasminogen activator (tPA) is a serine prot

189 e best-known function of the serine protease tissue-type plasminogen activator (tPA) is as a thrombol

190 Tissue-type plasminogen activator (tPA) is known to prom

191 Tissue-type plasminogen activator (tPA) is one of the ma

192 Tissue-type plasminogen activator (tPA) is the major int

193 1 (PAI-1), a rapid inhibitor of both uPA and tissue-type plasminogen activator (tPA) is the major phy

194 Tissue-type plasminogen activator (tPA) is the only ther

195 Thrombolysis with tissue-type plasminogen activator (tPA) is used for the

196 estatic liver disease in mice suggested that tissue-type plasminogen activator (tPA) or urokinase pla

197 Tissue-type plasminogen activator (tPA) promoted TGF-bet

198 Tissue-type plasminogen activator (tPA) regulates physio

199 Immunodepletion of tissue-type plasminogen activator (tPA) resulted in part

200 ranular colocalization of GH with endogenous tissue-type plasminogen activator (tPA) was also demonst

201 strated benefit to expanding the intravenous tissue-type plasminogen activator (tPA) window from 3 to

202 domized, blinded, dose-ranging comparison of tissue-type plasminogen activator (TPA) with a direct-ac

203 Tissue-type plasminogen activator (tPA), a protease up-r

204 Tissue-type plasminogen activator (tPA), a serine protea

205 on of some early markers of differentiation, tissue-type plasminogen activator (tPA), AFP and keratin

206 urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA), and plasma kall

207 activator (uPA), urokinase receptor (uPAR), tissue-type plasminogen activator (tPA), and plasminogen

208 L insertion for reactions with beta-trypsin, tissue-type plasminogen activator (tPA), and urokinase.

209 roserpin, a recently identified inhibitor of tissue-type plasminogen activator (tPA), is primarily lo

210 d thrombolysis, with either streptokinase or tissue-type plasminogen activator (tPA), on argatroban's

211 ll-free system, plasminogen activators [uPA, tissue-type plasminogen activator (tPA), or streptokinas

212 PAI-1, the primary physiologic regulator of tissue-type plasminogen activator (tPA), prolonged the t

213 n the luminal surface expressed the mRNA for tissue-type plasminogen activator (TPA), urokinase type

214 a showed a temporally enhanced expression of tissue-type plasminogen activator (tPA), urokinase-type

215 Whereas tissue-type plasminogen activator (tPA), which converts

216 oxypeptidase activity in human plasma delays tissue-type plasminogen activator (TPA)-induced clot lys

217 logical effect of ICAM-directed targeting of tissue-type plasminogen activator (tPA).

218 tor (uPA), and can also produce both uPA and tissue-type plasminogen activator (tPA).

219 mpared to those of a known HGF/SF activator, tissue-type plasminogen activator (tPA).

220 dard thrombolytic treatment with recombinant tissue-type plasminogen activator (tPA).

221 e expression of a known activator of HGF/SF, tissue-type plasminogen activator (tPA).

222 family that binds several ligands, including tissue-type plasminogen activator (tPA).

223 namic transfection of a plasmid encoding for tissue-type plasminogen activator (tPA).

224 Using mice deficient in tissue-type plasminogen activator (tPA-/-) and urokinase

225 Thrombolytics (eg, tissue-type plasminogen activator [tPA]) cannot be used

226 hy confirmed clot dissolution in recombinant tissue-type plasminogen activator-treated animals, but e

227 here were 15 191 of 44 410 (34%) intravenous tissue-type plasminogen activator-treated IS patients wi

228 of the thrombus was detected in recombinant tissue-type plasminogen activator-treated rats but not i

229 ve thrombosis model) followed by recombinant tissue-type plasminogen activator treatment (10 mg/kg, I

230 red with prothrombin-deficient plasma delays tissue-type plasminogen activator-triggered lysis; this

231 Additionally, tissue-type plasminogen activator triggers activation of

232 not observed with proteases like trypsin and tissue-type plasminogen activator, unless the RGD sequen

233 mice individually deficient for plasminogen, tissue-type plasminogen activator, urokinase-type plasmi

234 The mean dose of tissue-type plasminogen activator used was 48.7+/-29.5 m

235 Between 2004 and 2012, tissue-type plasminogen activator was administered to 24

236 Recently, thrombolytic therapy with tissue-type plasminogen activator was approved for selec

237 Plasminogen activation by tissue-type plasminogen activator was greatly accelerate

238 Median levels of tissue-type plasminogen activator were also significantl

239 modulates the interaction of plasminogen and tissue-type plasminogen activator with cultured human en

240 in(ogen) alphaC-domains bind plasminogen and tissue-type plasminogen activator with high affinity in

241 TEMI enrolled in the Enoxaparin Tenecteplase-Tissue-Type Plasminogen Activator With or Without Glycop

242 Low-dose, slow infusion of tissue-type plasminogen activator with repeated doses as

243 s heparin; (3) streptokinase plus alteplase (tissue-type plasminogen activator) with intravenous hepa

244 ement and supplement intravenous recombinant tissue-type plasminogen activator within the first 3 hou

245 Analogous reaction of tissue-type plasminogen activator yields comparable NO p